Recently stock market analysts have updated their consensus ratings on shares of Biolase, Inc. (BIOL). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/13/2014 – Biolase, Inc. was downgraded to “hold” by analysts at WallachBeth Capital. They now have a USD 2.5 price target on the stock.

10/08/2013 – Biolase, Inc. was upgraded to “neutral” by analysts at Zacks. They now have a USD 2 price target on the stock.

Biolase, Inc. has a 50 day moving average of 1.40 and a 200 day moving average of 1.02. The stock’s market capitalization is 82.10M, it has a 52-week low of 0.60 and a 52-week high of 2.20.

The share price of the company (BIOL) was up +2.17%, with a high of 1.54during the day and the volume of Biolase, Inc. shares traded was 27877.

View other investors thoughts on Biolase, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.